 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 December 1993 | Volume 119 Issue 11 | Pages 1105-1112
Purpose: To compare the efficacy, safety, and cost-effectiveness of low-molecular-weight heparin with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.
Data Identification: Studies were identified by MEDLINE search and review of bibliographies of retrieved articles. Hospital resources used in treating deep vein thrombosis and bleeding complications after total hip arthroplasty were estimated using retrospectively collected data from 447 patients who participated in a recently completed randomized controlled deep vein thrombosis prophylaxis trial at our center.
Study Selection: Randomized controlled trials directly comparing a low-molecular-weight heparin preparation with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty were potentially eligible for the meta-analysis.
Data Extraction: Data from eligible studies were extracted independently by two of the authors. Multiple regression analysis of data from the patient cohort was used to estimate the effect of deep vein thrombosis and bleeding on length of hospital stay. A hypothetical North American price for low-molecular-weight heparin was determined based on the ratio between low-molecular-weight heparin and standard heparin in France. Costs were based on weighted per-diem hospital expenditures and physician fees for procedures and reported in 1992 U.S. dollars.
Results of Data Synthesis: Meta-analysis of six eligible trials determined that low-molecular-weight heparin was significantly more effective than standard heparin at preventing deep vein thrombosis after total hip arthroplasty (common odds ratio, 0.72; 95% CI, 0.53 to 0.95). However, this benefit was restricted to the prevention of proximal deep vein thrombosis (common odds ratio, 0.40; CI, 0.28 to 0.59). No significant differences were found in the rates of distal deep vein thrombosis or total, major, or minor bleeding between the two groups. Based on a 2.6 to 1 price ratio between low-molecular-weight heparin and standard heparin, use of low-molecular-weight heparin would save the health care system about $50 000 per 1000 patients treated. Sensitivity analysis shows that if the low-molecular-weight heparin/standard heparin price ratio exceeds 3.7 (the threshold value lies between 0.8 and 5.5 based on the extremes of the 95% CI of the common odds ratios for deep vein thrombosis and bleeding complications), use of low-molecular-weight heparin is more expensive. At a price ratio of 10, it would cost more than $250 000 to treat 1000 patients with low-molecular-weight heparin compared with standard heparin or about $5000 for each additional deep vein thrombosis prevented with low-molecular-weight heparin.
Conclusions: Low-molecular-weight heparin is more effective and is at least as safe as standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Based on the current French price ratio of low-molecular-weight heparin to standard heparin, the use of low-molecular-weight heparin in North America would result in overall savings in cost; however, the relative cost-effectiveness is critically dependent on the price ratio between the two drugs. Further research is needed to compare the cost-effectiveness of low-molecular-weight heparin with other prophylactic regimens and postoperative deep vein thrombosis management strategies.
Author and Article Information
From McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario.
REVIEW
Efficacy and Cost of Low-Molecular-Weight Heparin Compared with Standard Heparin for the Prevention of Deep Vein Thrombosis after Total Hip Arthroplasty
Requests for Reprints: David Anderson, MD, Room 132, West Wing, Mackenzie Building, 5578 University Avenue, Halifax, Nova Scotia, Canada B3H 1Y8.
Acknowledgment: The authors thank Mrs. Debbie Redshaw for data collection.
Grant Support: Dr. Anderson was a Research Fellow with the Canadian Heart and Stroke Foundation when this study was done. Dr. Levine is a Career Scientist with the Medical Research Council of Canada. Dr. Wells is the recipient of a McLaughlin fellowship from the University of Ottawa. Dr. Hirsh is a Distinguished Professor of the Ontario Heart and Stroke Foundation.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kulik, F. D. Rubens, P. S. Wells, C. Kearon, T. G. Mesana, J. van Berkom, and B.-K. Lam Early Postoperative Anticoagulation After Mechanical Valve Replacement: A Systematic Review Ann. Thorac. Surg., February 1, 2006; 81(2): 770 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Martel, J. Lee, and P. S. Wells Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood, October 15, 2005; 106(8): 2710 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Lieberman and W. K. Hsu Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2097 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 338S - 400S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Tonnessen and S. R. Money Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2004; 16(2): 144 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 A. G. G. Turpie, K. A. Bauer, B. I. Eriksson, and M. R. Lassen Clinical Relevance of Bleeding Index--Reply Arch Intern Med, December 8, 2003; 163(22): 2794 - 2795. [Full Text] [PDF]
|
|
|
|
 |
|
 H A E M van Heereveld, R F J M Laan, F H J van den Hoogen, M C d. W. Malefijt, I R O Novakova, and L B A van de Putte Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement Ann Rheum Dis, October 1, 2001; 60(10): 974 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF]
|
|
|
|
 |
|
 G. K Bell and S. Z Goldhaber Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement Vascular Medicine, February 1, 2001; 6(1): 23 - 29. [Abstract] [PDF]
|
|
|
|
|
|
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Freedman, K. R. Brookenthal, R. H. Fitzgerald, S. Williams, and J. H. Lonner A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty J. Bone Joint Surg. Am., July 1, 2000; 82(7): 929 - 929. [Abstract] [Full Text]
|
|
|
|
|
|
P. J. Zed, J. E. Tisdale, and S. Borzak Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes Arch Intern Med, September 13, 1999; 159(16): 1849 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lotke and J. A. Heit Risks vs Benefits in Total Joint Surgery Chest, September 1, 1999; 116(3): 843 - 845. [Full Text] [PDF]
|
|
|
|
|
|
E. Etchells, R. S. McLeod, W. Geerts, P. Barton, and A. S. Detsky Economic Analysis of Low-Dose Heparin vs the Low-Molecular-Weight Heparin Enoxaparin for Prevention of Venous Thromboembolism After Colorectal Surgery Arch Intern Med, June 14, 1999; 159(11): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Gould, A. D. Dembitzer, G. D. Sanders, and A. M. Garber Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann Intern Med, May 18, 1999; 130(10): 789 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. SARMIENTO and A. D. K. GOSWAMI Thromboembolic Prophylaxis with Use of Aspirin, Exercise, and Graded Elastic Stockings or Intermittent Compression Devices in Patients Managed with Total Hip Arthroplasty J. Bone Joint Surg. Am., March 1, 1999; 81(3): 339 - 46. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Petticrew and S. C Kennedy Detecting the effects of thromboprophylaxis: the case of the rogue reviews BMJ, September 13, 1997; 315(7109): 665 - 668. [Full Text]
|
|
|
|
 |
|
 J. I. Weitz Low-Molecular-Weight Heparins N. Engl. J. Med., September 4, 1997; 337(10): 688 - 699. [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hull, G. E. Raskob, G. F. Pineo, W. Feldstein, D. Rosenbloom, A. Gafni, D. Green, J. Feinglass, A. A. Trowbridge, C. G. Elliott, et al. Subcutaneous Low-Molecular-Weight Heparin vs Warfarin for Prophylaxis of Deep Vein Thrombosis After Hip or Knee Implantation: An Economic Perspective Arch Intern Med, February 10, 1997; 157(3): 298 - 303. [Abstract] [PDF]
|
|
|
|
|
|
D. Bergqvist, G. Benoni, O. Bjorgell, H. Fredin, U. Hedlundh, S. Nicolas, P. Nilsson, and G. Nylander Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip Replacement N. Engl. J. Med., September 5, 1996; 335(10): 696 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Sarasin and H. Bounameaux Antithrombotic Strategy After Total Hip Replacement: A Cost-effectiveness Analysis Comparing Prolonged Oral Anticoagulants With Screening for Deep Vein Thrombosis Arch Intern Med, August 12, 1996; 156(15): 1661 - 1668. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Prandoni, S. Z. Goldhaber, A. Piccioli, and A. Girolami State-of-the-Art Review : Prevention of Venous Thromboembolism in Major Orthopedic Surgery Clinical and Applied Thrombosis/Hemostasis, July 1, 1996; 2(3): 153 - 157. [Abstract] [PDF]
|
|
|
|
|
|
J. Hirsh and J. Hoak Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association Circulation, June 15, 1996; 93(12): 2212 - 2245. [Full Text]
|
|
|
|
 |
|
 J. M. Gore and J. E. Dalen Cardiovascular Disease JAMA, June 7, 1995; 273(21): 1662 - 1664. [Abstract] [PDF]
|
|
|
|
|
|
A. W. A. Lensing, M. H. Prins, B. L. Davidson, and J. Hirsh Treatment of Deep Venous Thrombosis With Low-Molecular-Weight Heparins: A Meta-analysis Arch Intern Med, March 27, 1995; 155(6): 601 - 607. [Abstract] [PDF]
|
|
|
|
|
|
E. E. Weinmann and E. W. Salzman Deep-Vein Thrombosis N. Engl. J. Med., December 15, 1994; 331(24): 1630 - 1641. [Full Text]
|
|
|
|
|
|
A. T. Gentile, T. G. DeLoughery, and J. M. Porter Novel Antithrombotic Agents in Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1994; 7(2): 57 - 72. [PDF]
|
|
